Literature DB >> 19036907

A population-based record linkage study of mortality in hepatitis C-diagnosed persons with or without HIV coinfection in Scotland.

Scott A McDonald1, Sharon J Hutchinson, Sheila M Bird, Peter R Mills, John Dillon, Mick Bloor, Chris Robertson, Martin Donaghy, Peter Hayes, Lesley Graham, David J Goldberg.   

Abstract

Infection with the hepatitis C virus (HCV) is known to increase the risk of death from severe liver disease and, because HCV status is strongly associated with a history of injecting drug use, the effect of a key disease progression cofactor, infection with human immunodeficiency virus (HIV), is of interest. We examined all-cause, liver-related and drug-related mortality and excess risk of death from these causes in a large cohort of HCV-monoinfected and HIV-coinfected persons in Scotland. The study population consisted of 20,163 persons confirmed to be infected with hepatitis C through laboratory testing in Scotland between 1991 and 2005. Records with sufficient identifiers were linked to the General Register Office for Scotland death register to retrieve associated mortality data, and were further linked to a national database of HIV-positive individuals to determine coinfection status. A total of 1715 HCV monoinfected and 305 HIV coinfected persons died of any cause during the follow-up period (mean of 5.4 and 6.4 years, respectively). Significant excess mortality was observed in both HCV monoinfected and HIV coinfected populations from liver-related underlying causes (standardised mortality ratios of 25, 95% CI = 23-27; and 37, 95% CI = 26-52 for the two groups, respectively) and drug-related causes (25, 95% CI = 23-27; 39, 95% CI = 28-53. The risk of death from hepatocellular carcinoma, alcoholic or non-alcoholic liver disease, or from a drug-related cause, was greatly increased compared with the general Scottish population, with the highest standardised mortality ratio observed for hepatocellular carcinoma in the monoinfected group (70, 95% CI = 57-85). This study has revealed considerable excess mortality from liver- and drug-related causes in the Scottish HCV-diagnosed population; these data are crucial to inform on the clinical management, and projected future public health burden, of HCV infection.

Entities:  

Mesh:

Year:  2008        PMID: 19036907     DOI: 10.1177/0962280208094690

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  14 in total

Review 1.  Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis.

Authors:  Nathan Ford; Catherine Kirby; Kasha Singh; Edward J Mills; Graham Cooke; Adeeba Kamarulzaman; Philipp duCros
Journal:  Bull World Health Organ       Date:  2012-02-03       Impact factor: 9.408

Review 2.  Epidemiology and natural history of HCV infection.

Authors:  Behzad Hajarizadeh; Jason Grebely; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-02       Impact factor: 46.802

3.  Mortality among British Columbians testing for hepatitis C antibody.

Authors:  Amanda Yu; John J Spinelli; Darrel A Cook; Jane A Buxton; Mel Krajden
Journal:  BMC Public Health       Date:  2013-04-02       Impact factor: 3.295

4.  Trends in all cause and viral liver disease-related hospitalizations in people with hepatitis B or C: a population-based linkage study.

Authors:  Heather F Gidding; Gregory J Dore; Janaki Amin; Matthew G Law
Journal:  BMC Public Health       Date:  2011-01-24       Impact factor: 3.295

5.  Mortality of those who attended drug services in Scotland 1996-2006: record-linkage study.

Authors:  Elizabeth L C Merrall; Sheila M Bird; Sharon J Hutchinson
Journal:  Int J Drug Policy       Date:  2011-06-30

6.  Projections of the current and future disease burden of hepatitis C virus infection in Malaysia.

Authors:  Scott A McDonald; Maznah Dahlui; Rosmawati Mohamed; Herlianna Naning; Fatiha Hana Shabaruddin; Adeeba Kamarulzaman
Journal:  PLoS One       Date:  2015-06-04       Impact factor: 3.240

7.  Are there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.

Authors:  Mojca Maticic; Jerneja Videcnik Zorman; Sergeja Gregorcic; Eberhard Schatz; Jeffrey V Lazarus
Journal:  BMC Infect Dis       Date:  2014-09-19       Impact factor: 3.090

8.  Mortality in the Melbourne injecting drug user cohort study (MIX).

Authors:  Dhanya Nambiar; Paul A Agius; Mark Stoové; Matthew Hickman; Paul Dietze
Journal:  Harm Reduct J       Date:  2015-12-09

9.  Injecting drug users in Scotland, 2006: Listing, number, demography, and opiate-related death-rates.

Authors:  Ruth King; Sheila M Bird; Antony Overstall; Gordon Hay; Sharon J Hutchinson
Journal:  Addict Res Theory       Date:  2012-08-20

10.  A record-linkage study of the development of hepatocellular carcinoma in persons with hepatitis C infection in Scotland.

Authors:  S A McDonald; S J Hutchinson; S M Bird; C Robertson; P R Mills; J F Dillon; D J Goldberg
Journal:  Br J Cancer       Date:  2008-09-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.